PURPOSE: Recent development of drugs that target specific pathways in tumors has increased scientific interest in studying drug effects on tumor tissue. As a result, biopsies have become an important part of many early-phase clinical trials. Performing nondiagnostic tumor biopsies raises technical and ethical concerns mostly related to the use of a potentially harmful procedure with no potential benefit to the patient. This issue is complicated by uncertainty about whether performing biopsies in irradiated fields adds significant risk. This article reviews the clinical, scientific, and ethical considerations involved in performing nondiagnostic tumor biopsies in competent adults for research purposes, with a focus on biopsies performed in the setting of therapeutic irradiation. METHODS: Clinical trials that performed biopsies during or within 4 months of the completion of radiotherapy were identified with a literature review. RESULTS: Twenty-nine studies with 2,160 patients were identified. Sixteen of 29 studies reported adverse events (AEs) but did not report active evaluation for biopsy complications. Ten studies did not mention AEs within the study report. At least three studies actively evaluated patients for biopsy complications. Taking this into consideration, 17 (>1%) of 2,160 patients were reported to have biopsy complications, although reporting of AEs was suboptimal in most studies. CONCLUSION: Limited data suggest that biopsies can be performed in irradiated tissues without clinically significant excess risk. Ongoing and future trials including nondiagnostic research biopsies should record and report AEs related to this procedure to provide additional data on safety and toxicity.
PURPOSE: Recent development of drugs that target specific pathways in tumors has increased scientific interest in studying drug effects on tumor tissue. As a result, biopsies have become an important part of many early-phase clinical trials. Performing nondiagnostic tumor biopsies raises technical and ethical concerns mostly related to the use of a potentially harmful procedure with no potential benefit to the patient. This issue is complicated by uncertainty about whether performing biopsies in irradiated fields adds significant risk. This article reviews the clinical, scientific, and ethical considerations involved in performing nondiagnostic tumor biopsies in competent adults for research purposes, with a focus on biopsies performed in the setting of therapeutic irradiation. METHODS: Clinical trials that performed biopsies during or within 4 months of the completion of radiotherapy were identified with a literature review. RESULTS: Twenty-nine studies with 2,160 patients were identified. Sixteen of 29 studies reported adverse events (AEs) but did not report active evaluation for biopsy complications. Ten studies did not mention AEs within the study report. At least three studies actively evaluated patients for biopsy complications. Taking this into consideration, 17 (>1%) of 2,160 patients were reported to have biopsy complications, although reporting of AEs was suboptimal in most studies. CONCLUSION: Limited data suggest that biopsies can be performed in irradiated tissues without clinically significant excess risk. Ongoing and future trials including nondiagnostic research biopsies should record and report AEs related to this procedure to provide additional data on safety and toxicity.
Authors: D L Kwong; J Nicholls; W I Wei; D T Chua; J S Sham; P W Yuen; A C Cheng; K Y Wan; P W Kwong; D T Choy Journal: Cancer Date: 1999-04-01 Impact factor: 6.860
Authors: A Gürlek; M J Miller; A A Amin; G R Evans; G P Reece; B J Baldwin; M A Schusterman; S S Kroll; G L Robb Journal: J Reconstr Microsurg Date: 1998-07 Impact factor: 2.873
Authors: M Flam; M John; T F Pajak; N Petrelli; R Myerson; S Doggett; J Quivey; M Rotman; H Kerman; L Coia; K Murray Journal: J Clin Oncol Date: 1996-09 Impact factor: 44.544
Authors: W U Shipley; K A Winter; D S Kaufman; W R Lee; N M Heney; W R Tester; B J Donnelly; P M Venner; C A Perez; K J Murray; R S Doggett; L D True Journal: J Clin Oncol Date: 1998-11 Impact factor: 44.544
Authors: Stacey L Berg; Naomi Winick; Ashish Mark Ingle; Peter C Adamson; Susan M Blaney Journal: Pediatr Blood Cancer Date: 2010-07-15 Impact factor: 3.167
Authors: Christine M Parseghian; Kanwal Raghav; Robert A Wolff; Joe Ensor; James Yao; Lee M Ellis; Alda L Tam; Michael J Overman Journal: Clin Cancer Res Date: 2017-07-28 Impact factor: 12.531
Authors: Yaacov Richard Lawrence; Bhadrasain Vikram; James J Dignam; Arnab Chakravarti; Mitchell Machtay; Boris Freidlin; Naoko Takebe; Walter J Curran; Soren M Bentzen; Paul Okunieff; C Norman Coleman; Adam P Dicker Journal: J Natl Cancer Inst Date: 2012-12-10 Impact factor: 13.506
Authors: Jeffrey Peppercorn; Iuliana Shapira; Deborah Collyar; Teresa Deshields; Nancy Lin; Ian Krop; Hans Grunwald; Paula Friedman; Ann H Partridge; Richard L Schilsky; Monica M Bertagnolli Journal: J Clin Oncol Date: 2010-04-20 Impact factor: 44.544
Authors: Jung-min Lee; John L Hays; Anne M Noonan; Jennifer Squires; Lori Minasian; Christina Annunziata; Bradford J Wood; Minshu Yu; Katherine R Calvo; Nicole Houston; Nilofer Azad; Elise C Kohn Journal: Cancer Date: 2012-12-20 Impact factor: 6.860
Authors: Randall J Kimple; Janet K Horton; Chad A Livasy; Janiel M Shields; Julia A Lawrence; Wingkeung M Chiu; Anastasia Ivanova; David W Ollila; Lisa A Carey; Jan S Halle; Carolyn I Sartor; E Claire Dees Journal: Oncologist Date: 2012-09-24
Authors: Michael J Overman; Janhavi Modak; Scott Kopetz; Ravi Murthy; James C Yao; Marshall E Hicks; James L Abbruzzese; Alda L Tam Journal: J Clin Oncol Date: 2012-11-05 Impact factor: 44.544